Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Tabletop particle accelerator could transform medicine and materials science 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
